Intervention to Reduce Injection Drug Use - Full Text View

Purpose

This is a five-year prospective randomized trial comparing two intervention conditions designed to facilitate substance abuse treatment entry and enhance retention in order to reduce the behaviors associated with HIV and HCV risk among injection drug users (IDUs) and to improve client overall functioning. The overall goal of this project is to compare strengths-based case-management (CM) to an enhanced version of CM that uses case managers to facilitate a therapeutic alliance (CM/FTA) among out-of-treatment IDUs in Denver.

Condition	Intervention
Substance Abuse	Behavioral: Strengths-based case management Behavioral: Case management plus facilitated treatment alliance


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Intervention to Reduce Injection Drug Use

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:

Treatment entry and retention [ Time Frame: Baseline, 6 months after baseline, 12 months after baseline ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Drug injection and HIV/HCV risk behaviors [ Time Frame: Baseline, 6 months after baseline, 12 months after baseline ] [ Designated as safety issue: No ]


Enrollment:	726
Study Start Date:	November 2007
Study Completion Date:	February 2013
Primary Completion Date:	December 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Case Management	Behavioral: Strengths-based case management Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
Experimental: Facilitated Treatment Alliance	Behavioral: Case management plus facilitated treatment alliance Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.

Arms

Assigned Interventions

Experimental: Case Management

Behavioral: Strengths-based case management

Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.

Experimental: Facilitated Treatment Alliance

Behavioral: Case management plus facilitated treatment alliance

Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

opiate injection at least 3 times a week during the last 6-months
18 years of age or older
no drug abuse treatment in the 30-days prior to the interview
not transient
no known reason (e.g. pending jail time) why they will not be available for follow-up interviews
not involved in Project Safe research activities in the previous 12 months
willing to meet with an Addiction Research and Treatment Services (methadone clinic) counselor
eligible to be treated at ARTS

Exclusion Criteria:

too intoxicated or impaired mentally to voluntarily consent to participate in the project and/or respond to the interview

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00786630

Locations


United States, Colorado
Project Safe
Denver, Colorado, United States, 80205

Sponsors and Collaborators

University of Colorado, Denver

National Institutes of Health (NIH)

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	Robert E. Booth, Ph.D.	University of Colorado, Denver

More Information


Responsible Party:	University of Colorado, Denver
ClinicalTrials.gov Identifier:	NCT00786630 History of Changes
Other Study ID Numbers:	06-1131 2R01DA009832-11
Study First Received:	November 4, 2008
Last Updated:	December 19, 2014
Health Authority:	United States: Institutional Review Board United States: Federal Government

Keywords provided by University of Colorado, Denver:


Drug treatment entry and retention Drug injection frequency HIV risk behaviors Hepatitis C risk behaviors

Additional relevant MeSH terms:


Substance-Related Disorders Chemically-Induced Disorders Mental Disorders

ClinicalTrials.gov processed this record on September 26, 2016